PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

EMP2 re-expression inhibits growth and enhances radiosensitivity in nasopharyngeal carcinoma.

Abstract Although radiation therapy is the primary treatment for nasopharyngeal carcinoma, radioresistance remains a major obstacle to successful treatment in many cases, and the exact underlying molecular mechanisms are still ill-defined. EMP2, epithelial membrane protein-2, was a recently identified potential oncogene involved in multiple biological processes including cell migration and cell proliferation. This study was to explore the potential relationship between EMP2 expression, nasopharyngeal carcinoma genesis, and radioresistance. EMP2 expression status in 98 nasopharyngeal carcinoma clinical samples was examined by immunohistochemical staining. As a result, most of the nasopharyngeal carcinoma tumor samples were weakly or negatively stained, while paired adjacent normal tissues were moderately or strongly stained. Moreover, patients with higher expression of EMP2 had significant longer survival times. EMP2 re-expression suppresses cell growth, induces S-phase cell cycle arrest, and promotes radiosensitivity and apoptosis in nasopharyngeal carcinoma cells. These results support that loss of EMP2 is common, and its re-expression may serve as an approach to enhance radiation sensitivity in nasopharyngeal carcinoma.
PMID
Related Publications

MicroRNA-138-5p controls sensitivity of nasopharyngeal carcinoma to radiation by targeting EIF4EBP1.

Protein N-arginine methyltransferase 5 promotes the tumor progression and radioresistance of nasopharyngeal carcinoma.

BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro.

MiR-24 enhances radiosensitivity in nasopharyngeal carcinoma by targeting SP1.

The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma.

Authors

Mayor MeshTerms
Keywords

EMP2

Nasopharyngeal carcinoma

radiation therapy

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28347228
OWN - NLM
STAT- MEDLINE
DA  - 20170328
DCOM- 20170407
LR  - 20170407
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 3
DP  - 2017 Mar
TI  - EMP2 re-expression inhibits growth and enhances radiosensitivity in
      nasopharyngeal carcinoma.
PG  - 1010428317695972
LID - 10.1177/1010428317695972 [doi]
AB  - Although radiation therapy is the primary treatment for nasopharyngeal carcinoma,
      radioresistance remains a major obstacle to successful treatment in many cases,
      and the exact underlying molecular mechanisms are still ill-defined. EMP2,
      epithelial membrane protein-2, was a recently identified potential oncogene
      involved in multiple biological processes including cell migration and cell
      proliferation. This study was to explore the potential relationship between EMP2 
      expression, nasopharyngeal carcinoma genesis, and radioresistance. EMP2
      expression status in 98 nasopharyngeal carcinoma clinical samples was examined by
      immunohistochemical staining. As a result, most of the nasopharyngeal carcinoma
      tumor samples were weakly or negatively stained, while paired adjacent normal
      tissues were moderately or strongly stained. Moreover, patients with higher
      expression of EMP2 had significant longer survival times. EMP2 re-expression
      suppresses cell growth, induces S-phase cell cycle arrest, and promotes
      radiosensitivity and apoptosis in nasopharyngeal carcinoma cells. These results
      support that loss of EMP2 is common, and its re-expression may serve as an
      approach to enhance radiation sensitivity in nasopharyngeal carcinoma.
FAU - Tang, Mei
AU  - Tang M
AD  - 1 Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and
      Technology of China, Chengdu, Sichuan, China.
AD  - 2 Laboratory of Tumor Biotherapy, Cancer Center, West China Hospital, Sichuan
      University and Collaborative Innovation Center, Chengdu, China.
FAU - Liu, Ru-Yan
AU  - Liu RY
AD  - 3 Department of oncology, FuLing Central Hospital, Chongqing, China.
FAU - Zhou, Cong
AU  - Zhou C
AD  - 2 Laboratory of Tumor Biotherapy, Cancer Center, West China Hospital, Sichuan
      University and Collaborative Innovation Center, Chengdu, China.
FAU - Yuan, Meng-Zhen
AU  - Yuan MZ
AD  - 1 Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and
      Technology of China, Chengdu, Sichuan, China.
FAU - Wu, Dong-Ming
AU  - Wu DM
AD  - 2 Laboratory of Tumor Biotherapy, Cancer Center, West China Hospital, Sichuan
      University and Collaborative Innovation Center, Chengdu, China.
FAU - Yuan, Zhu
AU  - Yuan Z
AD  - 2 Laboratory of Tumor Biotherapy, Cancer Center, West China Hospital, Sichuan
      University and Collaborative Innovation Center, Chengdu, China.
FAU - Zhang, Peng
AU  - Zhang P
AD  - 1 Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and
      Technology of China, Chengdu, Sichuan, China.
FAU - Lang, Jin-Yi
AU  - Lang JY
AD  - 1 Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan 
      Cancer Center, School of Medicine, University of Electronic Science and
      Technology of China, Chengdu, Sichuan, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (EMP2 protein, human)
RN  - 0 (Membrane Glycoproteins)
RN  - Nasopharyngeal carcinoma
SB  - IM
MH  - Adult
MH  - Aged
MH  - Apoptosis/genetics
MH  - Cell Cycle Checkpoints/genetics
MH  - Cell Line, Tumor/drug effects
MH  - Cell Movement/genetics
MH  - Cell Proliferation/*genetics/radiation effects
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Membrane Glycoproteins/*biosynthesis/genetics
MH  - Middle Aged
MH  - Nasopharyngeal Neoplasms/genetics/pathology/*radiotherapy
MH  - Radiation Tolerance/*genetics
OTO - NOTNLM
OT  - EMP2
OT  - Nasopharyngeal carcinoma
OT  - radiation therapy
EDAT- 2017/03/30 06:00
MHDA- 2017/04/08 06:00
CRDT- 2017/03/29 06:00
AID - 10.1177/1010428317695972 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Mar;39(3):1010428317695972. doi: 10.1177/1010428317695972.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>